Cabaletta Bio, Inc. (CABA)
2.91
-0.36
(-11.01%)
USD |
NASDAQ |
Sep 09, 16:00
2.96
+0.05
(+1.72%)
After-Hours: 06:37
Cabaletta Bio Enterprise Value : 288.70M for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | 288.70M |
| September 08, 2026 | 349.08M |
| September 04, 2026 | 382.62M |
| September 03, 2026 | 384.30M |
| September 02, 2026 | 399.40M |
| September 01, 2026 | 354.11M |
| August 31, 2026 | 322.24M |
| August 28, 2026 | 323.92M |
| August 27, 2026 | 367.53M |
| August 26, 2026 | 345.72M |
| August 25, 2026 | 340.69M |
| August 24, 2026 | 320.56M |
| August 21, 2026 | 325.60M |
| August 20, 2026 | 335.66M |
| August 19, 2026 | 320.56M |
| August 18, 2026 | 288.70M |
| August 17, 2026 | 285.34M |
| August 14, 2026 | 261.86M |
| August 13, 2026 | 255.15M |
| August 12, 2026 | 278.63M |
| August 11, 2026 | 268.57M |
| August 10, 2026 | 270.25M |
| August 07, 2026 | 268.57M |
| August 06, 2026 | 263.54M |
| August 05, 2026 | 255.15M |
| Date | Value |
|---|---|
| August 04, 2026 | 265.21M |
| August 03, 2026 | 251.80M |
| July 31, 2026 | 250.12M |
| July 30, 2026 | 256.83M |
| July 29, 2026 | 240.06M |
| July 28, 2026 | 258.51M |
| July 27, 2026 | 256.83M |
| July 24, 2026 | 251.80M |
| July 23, 2026 | 256.83M |
| July 22, 2026 | 261.86M |
| July 21, 2026 | 273.60M |
| July 20, 2026 | 261.86M |
| July 17, 2026 | 275.28M |
| July 16, 2026 | 248.44M |
| July 15, 2026 | 265.21M |
| July 14, 2026 | 248.44M |
| July 13, 2026 | 264.38M |
| July 10, 2026 | 299.60M |
| July 09, 2026 | 323.08M |
| July 08, 2026 | 325.60M |
| July 07, 2026 | 320.56M |
| July 06, 2026 | 305.47M |
| July 02, 2026 | 335.66M |
| July 01, 2026 | 302.11M |
| June 30, 2026 | 322.24M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 557.00M |
| Amgen, Inc. | 254.84B |
| Anika Therapeutics, Inc. | 266.28M |
| BioCryst Pharmaceuticals, Inc. | 2.731B |
| Imunon, Inc. | 8.026M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -51.02M |
| Total Expenses (Quarterly) | 51.02M |
| EPS Diluted (Quarterly) | -0.3375 |
| Earnings Yield | -54.36% |
| Normalized Earnings Yield | -54.36 |